Moderna Receives U.S. FDA Approval for Updated 2026-2027 Spikevax and mNEXSPIKE COVID-19 Vaccines
BLA FilingapprovedSpikevaxmNEXSPIKEPositive
AI Analysis
Summary
Moderna received FDA approval for supplemental Biologics License Applications for updated 2026-2027 formulations of its Spikevax and mNEXSPIKE COVID-19 vaccines.
Outcome Details
FDA approved supplemental Biologics License Applications (sBLA) for 2026-2027 formulas of Spikevax and mNEXSPIKE
Importance:8/10
Sentiment:
0.80
FDA approvalCOVID-19 vaccinesupplemental BLAproduct update
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on August 27, 2026 9:08 PM